DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy

Information source: Mustafa Kemal University
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension; Left Ventricular Hypertrophy

Intervention: valsartan (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Mustafa Kemal University

Official(s) and/or principal investigator(s):
Fatih Yalcin, M.D., Principal Investigator, Affiliation: Mustafa Kemal University: Turkey

Summary

The study hypothesis: Valsartan as an angiotensin II receptor blocker treatment has beneficial effects on both midwall mechanics and myocardial functions in hypertensive patients with Left ventricular hypertrophy.

Clinical Details

Official title: Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: change from baseline in midwall fractional shortening (mFS) and tissue Doppler systolic wave (Sm) measured by echocardiography at six months

Secondary outcome:

change from baseline in systolic and diastolic blood pressure at six months

change from baseline in left ventricular mass index measured by echocardiography at six months

Eligibility

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- hypertension with left ventricular hypertrophy

Exclusion Criteria:

- clinical or laboratory evidence of secondary hypertension

- heart failure

- ischemic heart disease

- valvular heart disease

- arrhythmias

- peripheral vascular disease

- chronic obstructive pulmonary disease

- neurologic disorders

- diabetes mellitus

- renal dysfunction

- notable systemic disease

Locations and Contacts

Mustafa Kemal University School of Medicine, Department of Cardiology, Antioch 31100, Turkey
Additional Information

Starting date: November 2006
Last updated: August 29, 2011

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017